NCT04648319 is a Phase 2 clinical trial of BMS-936558 in Cholangiocarcinoma, sponsored by American University of Beirut Medical Center.

Who is sponsoring NCT04648319?

NCT04648319 is sponsored by American University of Beirut Medical Center.

What drugs are being tested in NCT04648319?

Interventions in NCT04648319: BMS-936558.

What condition does NCT04648319 study?

NCT04648319 studies Cholangiocarcinoma.

Is NCT04648319 still recruiting?

NCT04648319 is currently terminated. Last updated 23 February 2022.

Last reviewed 2022-02-23 · How we verify

NCT04648319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

Terminated Phase 2 Last updated 23 February 2022

What this trial tests

Phase 2 trial testing BMS-936558 in Cholangiocarcinoma in 1 participant. Terminated before completion.

Timeline

15 April 2021

Primary endpoint
17 January 2022

17 January 2022

Quick facts

Lead sponsor	American University of Beirut Medical Center
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	15 April 2021
Primary completion	17 January 2022
Estimated completion	17 January 2022
Sites	4 locations across Belgium, Lebanon, Luxembourg

Drugs / interventions tested

BMS-936558 — full drug profile →

Conditions studied

Cholangiocarcinoma — all drugs for Cholangiocarcinoma →

Sponsor

American University of Beirut Medical Center

Who can join

18 and older, any sex, with Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an Open-label, single-arm, multicenter Phase II pilot study to assess the efficacy and safety of BMS-936558 with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Progress in Radiotherapy for Cholangiocarcinoma.
Wang N, Huang A, Kuang B, Xiao Y, et al · · 2022 · cited 23× · PMID 35515132 · DOI 10.3389/fonc.2022.868034
Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision.
Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M. · · 2022 · cited 20× · PMID 36291857 · DOI 10.3390/cancers14205074
Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma.
Jiang J, Diaz DA, Nuguru SP, Mittra A, et al · · 2022 · cited 15× · PMID 36612046 · DOI 10.3390/cancers15010050
Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Sarantis P, Tzanetatou ED, Ioakeimidou E, Vallilas C, et al · · 2021 · cited 10× · PMID 35035673
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.
Dadgar N, Arunachalam AK, Hong H, Phoon YP, et al · · 2024 · cited 8× · PMID 39335203 · DOI 10.3390/cancers16183232
A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO).
Elias C, Zeidan YH, Bouferraa Y, Mukherji D, et al · · 2022 · cited 6× · PMID 36503610 · DOI 10.1186/s12885-022-10373-1
The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study.
Chen L, Xu W, Qi WX, Xu F. · · 2023 · cited 1× · PMID 37033350 · DOI 10.21037/tcr-22-1151
Evolving role of radiation therapy in advanced/metastatic intrahepatic cholangiocarcinoma.
Sharma D, Meena BL. · · 2025 · PMID 41378071 · DOI 10.4292/wjgpt.v16.i4.109304

Verify or expand the search:

Other trials of BMS-936558

Trials testing the same drug.

NCT02061761 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies · Phase 1, PHASE2 · completed
NCT01721746 — A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced · Phase 3 · completed
NCT01176461 — Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 · Phase 1 · completed

Other recruiting trials for Cholangiocarcinoma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07291947 — PULSAR Combined With Immunotherapy and Chemotherapy · Phase 1, PHASE2 · recruiting
NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting

Other American University of Beirut Medical Center trials

Trials by the same sponsor.

NCT07387848 — Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lym · Phase 2 · not yet recruiting
NCT07111000 — Testing the Epley Maneuver for Treating Dizziness in the Emergency Department: A Randomized Study · NA · not yet recruiting
NCT07059624 — Femoral Arterial Cannulation in Pediatrics · NA · recruiting
NCT06777875 — COMT and OPRM1 Polymorphisms and Their Effect on Post-Operative Pain in Children · recruiting
NCT06815952 — Enhancing Difficult Laryngoscopy Prediction Through A Mixed Scoring System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04648319 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by American University of Beirut Medical Center
Last refreshed: 23 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04648319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing